Multi-Checkpoint Antibody Combination Therapy for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including antibody therapies targeting PD-1, TIM-3, and LAG-3, have limited efficacy in enhancing immunity and treating cancers due to incomplete understanding of their mechanisms and interactions.
Innovation Solution
A combination therapy using specific anti-PD-1, anti-TIM-3, and anti-LAG-3 antibodies that bind to specific epitopes, enhancing immune activation and overcoming immune checkpoint inhibition by cancer cells, administered alone or in combination to activate the patient's anti-cancer immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single antibody therapy targeting PD-1 is used, then immune response is enhanced, but efficacy is limited due to incomplete understanding of mechanisms and interactions
Solution Approach 1:
The patent combines multiple antibody therapies targeting different immune checkpoint proteins (PD-1, TIM-3, LAG-3) into a single comprehensive treatment regimen. This merging approach addresses the limited efficacy of single-target therapies by simultaneously blocking multiple inhibitory pathways, thereby enhancing overall immune response against cancer while managing therapy complexity through coordinated administration
2Reliability
If combination therapy with multiple antibodies is used, then immune activation is enhanced, but mechanism understanding becomes more complex
Solution Approach 1:
The patent segments the complex immune checkpoint system into distinct targetable components (PD-1, TIM-3, LAG-3), each addressed by specific antibodies with characterized mechanisms. This segmentation allows for systematic understanding of individual antibody functions while achieving synergistic effects through combination, thereby enhancing immune activation without completely losing mechanistic clarity
3Productivity
If current antibody therapies are used, then cancer treatment is provided, but clinical response is insufficient
Solution Approach 1:
The patent creates a composite therapeutic approach by combining antibodies against multiple immune checkpoint proteins (PD-1, TIM-3, LAG-3) into an integrated treatment regimen. This composite therapy leverages the complementary mechanisms of each antibody to achieve enhanced and sustained clinical response, overcoming the insufficiency of single-agent or dual-agent therapies through multi-target engagement
Data Source
AI summary
This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.